Pharmaceutical Technology: Do generics producers have what it takes to tackle complex and specialty drugs?

According to [Dr. Kevin] Schulman, “specialty” largely refers to the high cost they command and not necessarily their complexity. But there are some exceptions. For example, JAK inhibitors are oral drugs that feature a certain complexity, says Jonathan Watanabe, PhD, professor of Clinical Pharmacy at the University of California, Irvine.

Read the full article here.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Subscribe To Our Newsletter

Get updates From the UCI School of Pharmacy and Pharmaceutical Sciences

More To Explore

Uncategorized

Hispanic Heritage Month With Emily Castro

Emily Castro, a fourth-year, first-generation student in the PhD in pharmacological sciences program, shares advice to others forging new paths.

0 Shares
Share
Tweet
Share